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Abstract
Cyclin-dependent kinases (CDK) are rational cancer therapeutic
targets fraught with the development of acquired resistance by
tumor cells. Through metabolic and transcriptomic analyses, we
show that the inhibition of CDK4/6 leads to a metabolic repro-
gramming associated with gene networks orchestrated by the
MYC transcription factor. Upon inhibition of CDK4/6, an accumula-
tion of MYC protein ensues which explains an increased glutamine
metabolism, activation of the mTOR pathway and blunting of HIF-
1a-mediated responses to hypoxia. These MYC-driven adaptations
to CDK4/6 inhibition render cancer cells highly sensitive to inhibi-
tors of MYC, glutaminase or mTOR and to hypoxia, demonstrating
that metabolic adaptations to antiproliferative drugs unveil new
vulnerabilities that can be exploited to overcome acquired drug
tolerance and resistance by cancer cells.
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Introduction
Cell cycle regulation is frequently altered in cancer (Malumbres &
Barbacid, 2009). In particular, cyclin-dependent kinases 4 and 6
(CDK4/6) have been studied as therapeutic targets in cancer due to
their essential role in the regulation of cell cycle progression at the G1
restriction point (Malumbres & Barbacid, 2009; Peyressatre et al,
2015). Highly selective and potent small-molecule CDK4/6 inhibitors
have been developed and approved for clinical development (Fry et al,
2004; Finn et al, 2009; Leonard et al, 2012; Beaver et al, 2015). These
new generation inhibitors effectively impair the growth of tumors with
a strong reliance on CDK4/6-Cyclin D1 (Peyressatre et al, 2015;
O’Leary et al, 2016). Among these inhibitors, palbociclib (PD0332991)
has shown the most promising results in phase III studies (Beaver
et al, 2015; O’Leary et al, 2016). However, mechanisms of acquired
resistance to CDK4/6 inhibitors are beginning to emerge which include
loss of RB1 or CCNE1 amplification (Herrera-Abreu et al, 2016).
In spite of the large body of knowledge that has been amassed
about cell cycle regulation and the increasing recognition of the
importance of metabolic changes associated with cell cycle progres-
sion (Moncada et al, 2012; Diaz-Moralli et al, 2013), relatively little
is known of the metabolic adaptations undergone by cancer cells in
response to pharmacological inhibition of cell cycle regulators. To
extend the benefits of CDK4/6 inhibition and to mitigate acquired
resistance in cancer management, the adaptations of cancer cells to
CDK4/6 inhibition need to be investigated by exploring not only
altered signaling pathways but also their crosstalk with metabolic
reprogramming. In this regard, tumor metabolic reprogramming is
emerging as a key component of adaptive responses to drug-induced
stress that may unveil novel actionable vulnerabilities of cancer cells
(Maiso et al, 2015; Tarrado-Castellarnau et al, 2016). Specifically,
recent work by Franco et al has unveiled metabolic reprogramming
events and actionable metabolic targets, in particular mTOR, in
pancreatic cancer cells in response to palbociclib (Franco et al, 2016).
Herein, we have undertaken a systematic study of the conse-
quences on central carbon metabolism of the depletion or inhibition
of CDK4/6 in cancer cells. By complementing metabolic analysis
with transcriptomic data, we accurately depict relevant metabolic
shifts associated with CDK4/6 depletion, revealing that the upregu-
lation of MYC and its downstream network, which includes
glutaminolysis and mTOR signaling, is both a direct consequence of,
and a key adaptation to CDK4/6 inhibition.
Results
CDK4/6 depletion enhances glucose, glutamine, and amino
acid metabolism
With the aim of elucidating metabolic adaptive responses and the
emergence of potential vulnerabilities consequent to CDK4/6 deple-
tion or inhibition, we targeted CDK4/6 in HCT116 human colorectal
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carcinoma cells by using specific small interference (si) RNAs.
These cells bear a loss-of-function p16INK4a mutant allele and a
wild-type allele silenced through a hypermethylated promoter,
resulting in full loss of functional p16INK4a (Myohanen et al, 1998),
which can lead to a higher activation status of CDK4/6. Double
CDK4/6 knockdown in HCT116 cells (Fig 1A) was more effective in
reducing cell proliferation than depleting CDK4 or CDK6 alone
(Fig 1B), confirming that these kinases play compensatory roles
(Malumbres et al, 2004). CDK4/6 inhibition caused an increase in
cell volume but had no effect on the total cellular protein content
(Fig EV1A–D). In association with a reduced proliferation, knock-
down of CDK4/6 promoted early apoptosis (Fig 1C) and an expected
accumulation of cells in the G1 phase of the cell cycle (Fig 1D).
Equivalent results were obtained in HCT116 cells treated with the
selective CDK4/6 inhibitor PD0332991 (Fig EV1E–L).
Unexpected for the observed cell proliferation inhibitory activity,
knockdown of CDK4/6 or inhibition with PD0332991 enhanced
glucose and glutamine consumption as well as lactate and glutamate
production (Fig 1E), accompanied with greater production rates of
aspartate, asparagine, proline, glycine, and alanine and higher
consumption rates of serine, arginine, cysteine, threonine, isoleu-
cine, leucine, and lysine (Fig 1F).
Cells depleted of CDK4/6 displayed higher extracellular acidifi-
cation rate (ECAR) than control cells (Fig 1G), a reflection of higher
production of lactate derived from glycolysis. Real-time ECAR deter-
minations while adding glucose and oligomycin to cells cultured in
glucose-deprived medium identified an increase in glycolysis, glyco-
lytic capacity, and glycolytic reserve associated with CDK4/6 knock-
down (Fig 1H). Further evidence indicated that CDK4/6 depletion
favors glycolytic flux through the non-oxidative branch of the
pentose phosphate pathway (PPP) (Appendix Fig S1). In spite of
their higher glycolytic activity, CDK4/6-kd cells were less sensitive
to changes in glucose availability than control cells (Fig 1I), suggest-
ing that they may overcome glucose deprivation by increasing alter-
native metabolic pathways such as glutaminolysis or glycogenolysis
(Pelletier et al, 2012). Indeed, CDK4/6-kd cells presented higher
glycogen storage than control cells (Fig 1J).
CDK4/6 depletion enhances mitochondrial metabolism
and function
We next examined through 13C-isotope labeling experiments the
contribution of glucose to the tricarboxylic acid (TCA) cycle by
comparing the ratios of m2-labeled metabolites to m2 pyruvate, as
m2 is the most abundant isotopologue (mass isotopomer) derived
from [1,2-13C2]-glucose (Grassian et al, 2011) (Fig 1K, left). CDK4/6-
kd cells presented higher ratios of m2 citrate, glutamate, a-ketogluta-
rate, malate, and aspartate, indicating a greater incorporation of
labeled pyruvate into the TCA cycle than control cells (Fig 1K, right).
Because CDK4/6-kd cells consumed more glutamine and
produced more glutamate than control cells (Fig 1E), we examined
the fate of glutamine carbons by monitoring uniformly labeled
▸Figure 1. Effects of CDK4/6 knockdown on growth and glucose and glutamine metabolism of HCT116 cells.A Efficacy of siRNA-mediated knockdown of CDK4 and CDK6 in HCT116 cells, assessed by Western blotting.
B Effect of CDK4 and/or CDK6 knockdown on cell proliferation.
C Early apoptosis percentage in CDK4/6-kd and control cells assessed by flow cytometry.
D Cell cycle distribution in CDK4/6-kd and control cells determined by flow cytometry.
E Comparative extracellular metabolic fluxes for CDK4/6-kd and control cells. Glucose and glutamine consumption and lactate and glutamate production rates were
obtained after 24 h of incubation with fresh media and normalized to cell number.
F Non-essential (left) and essential (right) amino acid consumption and production rates in CDK4/6 knockdown and control cells obtained after 24 h of incubation
with fresh media and normalized to cell number. Asp, aspartate; Ser, serine; Asn, asparagine; Pro, proline; Gly, glycine; Ala, alanine; Arg, arginine; Cys, cysteine; Thr,
threonine; Ile, isoleucine; Leu, leucine; Lys, lysine.
G Basal extracellular acidification rates (ECAR) normalized to cell number.
H ECAR profiles illustrating glycolysis, glycolytic capacity, and glycolytic reserve in control (left) and CDK4/6 knockdown cells (right). Cells were incubated in the absence
of glucose, and sequential injections of glucose and oligomycin were performed. Data are normalized to cell number and represented as mean  SD from n = 5.
I Glucose dependence of CDK4/6-kd and control cells. Cultures were deprived of glucose (Glc) for 72 h, and the effect on cell proliferation was determined.
J Glycogen quantification in CDK4/6-kd and control cells normalized to cell number.
K Glucose contribution to the TCA cycle in CDK4/6-kd and control cells. Cells were incubated in the presence of 10 mM [1,2-13C2]-glucose for 24 h, and TCA
intermediates were isolated from cells for isotopologue distribution analysis. Left, schematic representation of the labeling distribution in TCA intermediates from
[1,2-13C2]-glucose in the first turn of the TCA cycle. The incorporation of
13C-labels to the TCA intermediates is considered to be via pyruvate dehydrogenase (PDH),
pyruvate carboxylase (PC), and malic enzyme (ME2). For clarity purposes, only the first turn of the TCA cycle is represented. Right, m2 citrate, m2 glutamate, m2
a-ketoglutarate (aKG), m2 malate, and m2 aspartate labeling ratios normalized to m2 pyruvate (pyr) labeling.
L Glutamine contribution to the TCA cycle in CDK4/6-kd and control cells. Cells were incubated in the presence of 2 mM [U-13C5]-glutamine for 24 h, and TCA
intermediates were isolated from cells for isotopologue distribution analysis. Schematic representation of the labeling distribution in TCA intermediates from
[U-13C5]-glutamine in the first turn of the TCA cycle considering the oxidative TCA cycle (red labeling) and the reductive carboxylation (green labeling). The
incorporation of 13C-labels to the TCA intermediates is considered to be via glutaminase and glutamate dehydrogenase. For clarity purposes, only the first turn of the
TCA cycle is depicted.
M Glutamine contribution to the TCA cycle in CDK4/6-kd and control cells. Right, normalized m4 citrate, m5 glutamate, m5 a-ketoglutarate (aKG), m4 malate, and m4
aspartate labeling are indicative of the oxidative TCA pathway. Values are normalized to total label enrichment (Σm). Left, normalized m5 citrate, m3 aspartate, and
m3 malate are obtained through the reductive carboxylation of [U-13C5]-glutamine. Values are normalized to total label enrichment (Σm).
N Quantification of intracellular metabolites related to mitochondrial metabolism (mean  SD of n = 4). Data are normalized by cell number and represented as a
percentage relative to control cells for each metabolite.
Data information: CDK4/6, CDK4/6-kd cells; Control, cells transfected with non-targeting RNA duplexes. All experiments were performed 96 h after siRNA transfection or
PD0332991 treatment. Shown values are mean  SD for n = 3 (except where otherwise indicated). Significance was determined by two-tailed independent sample Student’s
t-tests. Statistically significant differences between CDK4/6-inhibited and control cells are indicated as P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), while differences between
treatment (glucose deprivation) and the corresponding control are shown as P < 0.05 (#) for CDK4/6-inhibited cells and as P < 0.01 (¶¶) for control cells.
Source data are available online for this figure.
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[U-13C5]-glutamine incorporation into TCA cycle intermediates
(Fig 1L). Direct glutamine contribution to citrate (m4), glutamate
(m5), a-ketoglutarate (aKG) (m5), malate (m4), and aspartate (m4)
was significantly increased in CDK4/6-kd cells, demonstrating an
enhanced glutamine oxidation and consequent carbon contribution
to the oxidative TCA cycle (Fig 1M, right). CDK4/6-kd cells
presented higher levels of m5 citrate, m3 aspartate, and m3 malate
(Fig 1M, left), revealing a more active reductive carboxylation of
m5 a-ketoglutarate (Metallo et al, 2012; Fendt et al, 2013). Never-
theless, the relative proportion of m5 citrate, m3 aspartate and m3
malate versus m4 citrate, m4 aspartate, and m4 malate-labeled
species indicated that oxidative TCA cycle was the main pathway of
glutamine metabolism in both cases. Further, the concentration of
TCA intermediates and related metabolites was significantly
increased in CDK4/6-kd cells (Fig 1N).
CDK4/6-kd cells exhibited higher oxygen consumption rates
(OCR) than control cells (Fig 2A and B), indicating an augmented
mitochondrial respiration which is in agreement with recently
published studies (Franco et al, 2016). Under glutamine depriva-
tion, CDK4/6-kd cells maintained near-control levels of basal respi-
ration in complete medium (Fig 2C) and decreased the levels of
acidification (Fig 2D), evidencing a shift of glucose metabolism into
the TCA cycle and away from lactate production in the absence of
glutamine. Under glucose deprivation, OCR was increased by 2-fold
(Fig 2C), while a drop in ECAR was observed in CDK4/6-kd cells
(Fig 2D), indicating that enhanced glutamine mitochondrial
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metabolism may compensate for the reduced glycolytic ATP produc-
tion. Additional experiments evidenced that CDK4/6-kd cells shifted
to glutamine as the preferred substrate for respiration (Fig 2E–H),
thereby becoming more sensitive than control cells to the electron
transport chain component inhibitors FCCP (Fig 2I, left) and
rotenone + antimycin A (Fig 2I, right).
Collectively, these observations indicate that CDK4/6 knockdown
increases mitochondrial metabolism through elevated utilization of
glutamine and enhanced mitochondrial respiratory capacity and are in
agreement with Franco et al (2016) results for a pancreatic cancer cell
model. As such, specific metabolic reprogramming events in response
to CDK4/6 depletion or inhibition appear to be conserved among
cancer cells of different origin. Additional experiments showed that
CDK4/6 depletion increased glutathione, NADPH, and ROS levels,
while it impaired fatty acid synthesis in HCT116 cells (Fig EV2), all of
which are processes where glutamine is or can be involved.
A quantitative model of central carbon metabolism in CDK4/6-
depleted HCT116 cells
To infer differential intracellular metabolic flux distributions in
CDK4/6-kd versus control cells, we constructed a quantitative meta-
bolic network model of central carbon metabolism and performed a
13C metabolic flux analysis (Niedenfuhr et al, 2015) by applying the
MATLAB-based software package INCA (Young, 2014). For this, we
combined direct extracellular measurements, such as oxygen
consumption, metabolite consumption and production rates, and
protein synthesis rate, with isotopologue distributions in several
A
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Figure 2. Effect of CDK4/6 knockdown on the mitochondrial function of HCT116 cells.
A Oxygen consumption rate (OCR), following sequential injections of oligomycin (1.5 lM), FCCP (1 lM), and antimycin A (1 lM) + rotenone (1 lM), in control and
CDK4/6-kd cells.
B Quantification of OCR for basal respiration, ATP production-associated respiration, non-ATP linked oxygen consumption (proton leak), maximal respiration, spare
respiratory capacity, and non-mitochondrial respiration, in complete medium and normalized to cell number.
C OCR basal levels in complete and restricted (glucose- or glutamine-deprived) media conditions, normalized to cell number.
D ECAR basal levels under the conditions summarized in (C).
E Effects of glucose (left) and glutamine (right) deprivation on the mitochondrial function of CDK4/6-kd and control cells. OCR profiles were acquired following
injections of oligomycin (1.5 lM), FCCP (1 lM), antimycin A (1 lM) + rotenone (1 lM).
F Glucose and glutamine deprivation effects on maximal respiration.
G ATP production-associated respiration.
H Non-mitochondrial respiration.
I Effects of mitochondrial uncoupling and mitochondrial complex I and III inhibition on OCR after FCCP addition (left) or rotenone and antimycin A (right) addition in
complete and restricted media, expressed as Log2 (fold change). Results are normalized to cell number and shown as percentage of OCR relative to non-targeting
siRNA-treated cells cultured in complete medium. Cells were cultured for 1 h in glucose- or glutamine-deprived media (–Glc and –Gln, respectively) before
experimental determinations were made, and these conditions were maintained throughout the experiment.
Data information: CDK4/6, CDK4/6-kd cells; Control, cells transfected with non-targeting RNA duplexes. Bars correspond to mean  SD (n = 4). Significance was
determined by two-tailed independent sample Student’s t-tests. Statistically significant differences between CDK4/6 knockdown and control cells are indicated as
P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), while differences between treatment (oligomycin, glucose, or glutamine deprivation) and the corresponding control
(CDK4/6 siRNA- or non-targeting siRNA-treated cells in complete medium) are shown as P < 0.05 (#), P < 0.01 (##), and P < 0.001 (###) for CDK4/6-inhibited cells and
as P < 0.05 (¶), P < 0.01 (¶¶), and P < 0.001 (¶¶¶) for control cells.
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metabolites resulting from 13C propagation from labeled glucose and
glutamine. The outcome of this analysis was compatible with all
prior observations, supporting that CDK4/6-kd cells exhibit a higher
mitochondrial activity accompanied with a higher dependence on
glutamine and lower dependence on glucose (Fig 3 and Table EV1).
In addition, the increased glutamine uptake and transformation to
glutamate by glutaminase (GLS1) can also promote the mitochon-
drial respiratory activity since glutamate is the substrate for mito-
chondrial glutamate dehydrogenase (GDH). On the other hand, the
extra demand of amino acids for protein synthesis matched the
measured uptakes of essential amino acids in control cells, while
CDK4/6-inhibited cells exhibited an extra uptake of several amino
acids above the required value for protein synthesis (Appendix Fig S2).
MYC, mTOR, and HIF-1a are key players in the adaptive cellular
responses to CDK4/6 depletion
Gene expression profiling identified 1308 genes differentially
expressed in CDK4/6-kd versus control cells (718 upregulated, 592
downregulated; Fig 4A; see also Table EV2). Gene set enrichment
analysis (GSEA) (Subramanian et al, 2005) yielded a significant
enrichment in CDK4/6-kd cells of signatures associated with MYC
(upregulation), mechanistic target of rapamycin (mTOR) (upregula-
tion), or hypoxia inducible factor 1a (HIF-1a) (downregulation)
(Fig 4B; see also Table EV3). The inferred upregulation of the mTOR
pathway is in agreement with previous studies (Franco et al, 2016).
The expression levels of selected genes, including subsets encoding
enzymes of the central carbon metabolism (Duarte et al, 2007;
Schellenberger et al, 2010), were quantified by qRT–PCR. Consistent
with the observed increased respiratory activity and mitochondrial
function, genes associated with MYC and involved in glutamine and
polyamine metabolism or with a role in mitochondrial biogenesis
and function were overexpressed in CDK4/6-kd cells compared to
control cells (Fig 4C) (Dang, 2013).
The above results suggest that CDK4/6 knockdown activates
MYC-dependent functions. Indeed, CDK4/6 knockdown or inhibi-
tion with PD0332991 (Fig 5A; see also Fig EV4A) caused a signifi-
cant accumulation of MYC as compared to control cells under
standard growth conditions. Consistent with the known ubiquitin–
proteasome-dependent turnover of MYC (Farrell & Sears, 2014), its
relatively low levels in control cells were upregulated by treatment
with the proteasome inhibitor MG132 (Fig 5A). This potential mode
of degradation in a putative CDK4/6-dependent turnover of MYC
was further supported by the observation of higher levels of poly-
ubiquitin-conjugated MYC species in control than in CDK4/6-kd
cells (Fig 5B). It has been recently reported that MYC peptides are
substrates of the kinase activity of CDK4/6 (Anders et al, 2011). In
order to test this hypothesis, we performed in vitro kinase assays
with CDK4-Cyclin D1 or CDK6-Cyclin D1 complexes and full-length
recombinant human c-MYC protein (Abcam, ab169901) as a
substrate. Indeed, we detected specific 33P signals in both kinase
reactions, indicating that both CDK4-Cyclin D1 and CDK6-Cyclin D1
complexes directly phosphorylate MYC (Fig 5D). With the purpose
of determining the precise phosphorylation sites, we performed
kinase assays with unlabeled ATP and analyzed MYC tryptic
peptides by mass spectrometry. The results showed that peptides
KFELLPT(phosphor)PPLSPSR and KFELLPTPPLS(phosphor)PSRR
were phosphorylated on threonine 7 (corresponding to c-MYC T58)
and serine 11 (corresponding to c-MYC S62), respectively
(Fig EV3A). Moreover, CDK4/6-kd cells displayed diminished
P-MYC (Thr58)/MYC and P-MYC (Ser62)/MYC ratios compared to
control cells (Fig 5C), supporting that phosphorylation of MYC at
Thr58 and Ser62 is mediated by CDK4/6 in live cells. Consistently,
cells expressing the MYC T58A phospho-resistant mutant mimicked
the metabolic phenotype induced by CDK4/6 inhibition, as shown
by enhancing glucose and glutamine consumption as well as lactate
and glutamate production (Fig EV3B). Collectively, these observa-
tions suggest that CDK4/6-dependent phosphorylation is associated
with the polyubiquitination and subsequent proteasomal degrada-
tion of MYC, thus offering a plausible mechanism for the accumula-
tion of MYC upon inhibition of CDK4/6.
In agreement with the transcriptomic analysis, MYC upregulation
in response to CDK4/6 knockdown or inhibition was accompanied
with increased protein levels of glutaminase (GLS1) (Fig 5E; see
also Fig EV4A), positively regulated by MYC through transcriptional
repression of microRNA-23a/b (Gao et al, 2009). The GLS1 gene
encodes two alternatively spliced isoforms, kidney glutaminase or
KGA and glutaminase C or GAC (Mates et al, 2013). By using
isoform-specific antibodies, we confirmed the overexpression of
both GLS1 isoforms in CDK4/6-kd HCT116 cells (Fig EV4B), consis-
tent with the increased glutamine consumption rates observed in
CDK4/6-kd cells (Fig 1E). Further support for MYC activation in
response to CDK4/6 depletion was provided by the observation of a
significant upregulation, determined by qRT–PCR, of known MYC-
regulated or associated genes, including GLS1, SLC7A5, SLC7A6,
MAX, and genes of polyamine synthetic pathways (Fig 5F; see also
Fig EV4C).
Our analysis additionally suggested that CDK4/6 knockdown
induced an upregulation of the mTOR pathway (Fig 4; see also
Table EV3), an inference experimentally supported by the observa-
tion of increased levels of P-mTOR (Ser2448) in CDK4/6-kd cells
under standard growth conditions (Fig 5E), in concordance with
recent studies (Franco et al, 2016). Intracellular glutamine acts
upstream of mTOR complex 1 (mTORC1) serving as an efflux
substrate for SLC7A5/SLC3A2, a plasma membrane heterodimer, to
regulate the uptake of extracellular leucine, and leading to mTORC1
activation (Nicklin et al, 2009). Indeed, CDK4/6-kd cells exhibited
enhanced glutamine and leucine uptake (Fig 1E and F) and upregu-
lation of SLC7A5 and SLC3A2 (Fig 5F), thus providing robust
evidence for this mechanism of activation of the mTOR pathway
upon CDK4/6 knockdown. Furthermore, mTORC1 promotes the use
of glutamine carbons through TCA anaplerosis by activating gluta-
mate dehydrogenase (GDH) (Csibi et al, 2013). Augmented levels of
TCA intermediates (Fig 1N) and the overexpression of GDH
(Fig EV4B) supported that an enhanced glutamine mitochondrial
metabolism followed CDK4/6 depletion. Further, downregulation of
tuberous sclerosis (TSC) 2 and TSC1, key mTOR-negative regulators
(Sabatini, 2006), was observed in CDK4/6-kd cells (Fig 5G). It has
been shown that MYC activates the mTOR signaling pathway through
direct repression of TSC2 (Ravitz et al, 2007). Thus, multiple mecha-
nisms may underlie the upregulation of the mTOR pathway induced
by the accumulation of MYC that follows CDK4/6 inhibition.
In addition, CDK4/6-kd cells displayed increased levels of P-Akt
(Ser473) (Fig 5G), a modification catalyzed by mTORC2 (Sarbassov
et al, 2005; Laplante & Sabatini, 2012). This was accompanied with
a downregulation of p27Kip1 (Fig 5G) and upregulation of PIK3R3
ª 2017 The Authors Molecular Systems Biology 13: 940 | 2017
Míriam Tarrado-Castellarnau et al CDK4/6 inhibition causes MYC addiction Molecular Systems Biology
5
Published online: October 4, 2017 
Figure 3. Metabolic shifts following CDK4/6 knockdown in HCT116 cells.
A quantitative 13C metabolic flux analysis was performed with experimental measures of label propagation from glucose and glutamine. The software package INCA
was applied to estimate flux values for all these processes, which involved a fitting procedure of predicted and measured values for labeled products (in purple) and
extracellular measured processes (in blue). Fold changes refer to CDK4/6-kd versus control cells and provide a measure of the changes in the flux calculated with the best fit
values. Color in arrows (red, black, green) indicates fold changes for reactions whose 95% confidence intervals are not overlapping. Fold changes for the reaction fluxes
whose 90% (R23 and R49) and 80% (E23, E27, R25-32, R38, and R45) confidence intervals are not overlapping are also included. For clarity purposes, some proteins (bold letters)
and genes (italic letters in round brackets) are shown. See Appendix and Table EV1 for abbreviations and a full description of the model, data, and the resulting flux map.
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(encoding the PI3K regulatory subunit p55c) and CCND1 (Cyclin
D1) (Fig EV4D), known to be mediated through inactivation of
FOXO3a by P-Akt (Biggs et al, 1999; Brunet et al, 1999).
The GSEA-predicted downregulation of hypoxia-associated
responses upon CDK4/6 knockdown correlated with lower expression
levels of HIF-1a and HIF-2a proteins in CDK4/6-kd cells than control
cells in normoxia (Fig 5E; see also Fig EV4F). This was accompanied
with an upregulation of pyruvate dehydrogenase (PDH) (Fig 5H) and
mitochondrial activities (Fig 5I), concomitant with a downregulation
of PDH kinases PDK1 and PDK3 (Fig 5H), targets of the transcrip-
tional activation of HIF-1a. The mitochondrial uptake of glutamate
was also increased in CDK4/6-kd cells, concomitant with an upregu-
lation of the glutamate transporter SLC25A13 (Fig EV4E). It has been
shown that increased glutaminolysis generates higher levels of
A
C
B
Figure 4. Transcriptomic analysis of CDK4/6 knockdown in HCT116 cells.
A Heatmap of differential gene expression of CDK4/6-kd versus control cells. Relative positions of selected genes are indicated on the right.
B GSEA enrichment plots showing the correlation of the expression profiles of CDK4/6-kd versus control cells of gene sets upregulated by MYC, upregulated in response
to hypoxia, downregulated after glutamine deprivation, downregulated in response to rapamycin, involved in G1/S transition, and involved in oxidative
phosphorylation.
C Expression levels of selected genes. Column 1, differentially expressed genes in CDK4/6-kd versus control identified from Affymetrix GeneChip analysis (Table EV2).
Column 2, gene expression levels determined by qRT–PCR (CDK4/6-kd versus control). Column 3, effect of hypoxia (1% O2) on gene expression in control HCT116 cells,
determined by qRT–PCR (1% O2 versus control). Column 4, effect of CDK4/6 knockdown on gene expression in HCT116 cells under hypoxia (1% O2), determined by
qRT–PCR (CDK4/6-kd + 1% O2 versus control + 1% O2). Data were blindly assessed.
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intracellular a-ketoglutarate, which is a substrate of, and activates,
prolyl hydroxylases (PHDs), triggering PHD-dependent HIF-1a
hydroxylation and proteasome-mediated degradation, even under
hypoxia (Fig 5E) (Tennant et al, 2009). Incubation of cells with the
PHD inhibitor DMOG upregulated HIF-1a in CDK4/6-kd cells
(Fig 5E), revealing that the observed reduction of HIF-1a levels in
normoxia is mediated by PHD hydroxylation. Conversely, hypoxia
caused a significant downregulation of MYC, GLS1 and P-mTOR
(Figs 4C and 5E), partially countering the upregulation of MYC subse-
quent to CDK4/6 knockdown (Gordan et al, 2007).
Importantly, several of the observed responses to CDK4/6
knockdown or inhibition were not limited to HCT116 cells. Thus,
treatment of MCF-7 or SK-BR-3 breast cancer cells with the CDK4/
6 inhibitor PD0332991 also caused an upregulation of MYC, GLS1
and the mTOR and Akt signaling pathways, as well as a downreg-
ulation of HIF-1a (Fig 5J), suggesting that upregulation of MYC,
with its consequent downstream effects, is an adaptive response
to CDK4/6 loss of function conserved among several types of
cancer cells.
Cells synchronized in the G1 phase of the cell cycle (Fig 5K) did
not accumulate MYC, GLS1 or P-mTOR as compared to asyn-
chronous cells, and presented higher HIF-1a levels than cells with
CDK4/6 inhibition (Fig 5L). We found the same results with
NCM460 human epithelial cells derived from healthy colon mucosa
(Fig EV4G and H). Further, the consumption and production rates
of glucose, glutamine, lactate and glutamate in G1-synchronized
cells were significantly lower than those of control HCT116 cells
(Fig 5M) and not significantly different from asynchronous NCM460
cells (Fig EV4I). These observations support the conclusion that the
modulation of MYC, GLS1, P-mTOR, and HIF-1a that follows CDK4/
6 depletion or inhibition is not a result of G1 arrest but directly attri-
butable to a loss of function of CDK4/6.
CDK4/6 depletion or inhibition sensitizes cells to the inhibition of
MYC, glutaminase, mTOR or PI3K or to hypoxia
We reasoned that the upregulation of MYC and its downstream
effector functions after CDK4/6 depletion or inhibition could make
the cells addicted to MYC (Yoo et al, 2008). In agreement with
previous studies (Lin et al, 2007), treatment with the MYC-MAX
heterodimerization inhibitor 10058-F4 (Yin et al, 2003) strongly
downregulated MYC protein levels causing a 60% decrease in
control cell numbers and a complete abrogation of proliferation in
CDK4/6-kd cells at 50 lM (Fig 6A). In addition, 10058-F4 treatment
caused a dose-dependent inhibition of cell proliferation and a rever-
sal of the effects of PD0332991 on GLS1, HIF-1a, P-mTOR, P-S6K,
and P-Akt protein levels (Fig 6B). Likewise, specific knockdown of
MYC with RNAi duplexes had the same effect as 10058-F4 treatment
to synergize with CDK4/6 knockdown in reducing cell proliferation
(Fig 6C) and to reverse the effects of CDK4/6 inhibition both on the
consumption and production rates of glucose, glutamine, lactate
and glutamate (Fig 6D) and on GLS1, HIF-1a, P-mTOR, P-S6K, and
P-Akt protein levels (Fig 6E).
As described above, the major MYC target and metabolic
effector glutaminase (GLS1) is significantly upregulated in CDK4/
6-kd HCT116 cells. Treatment of cells with the specific GLS1 inhi-
bitor bis-2-(5-phenylacetoamido-1,2,4-thiadiazol-2-yl)ethyl sulfide
(BPTES) (Robinson et al, 2007) for 72 h selectively reduced the
viability of CDK4/6-kd cells without significantly compromising
that of control cells (Fig 6F). In contrast, glutamine deprivation
▸Figure 5. CDK4/6 knockdown causes upregulation of MYC, GLS1, and P-mTOR and downregulation of HIF-1a.A CDK4/6 knockdown induces an upregulation of MYC. Western blotting analysis of total protein fractions of control and CDK4/6-kd cells after incubation with the
proteasome inhibitor MG132 or vehicle for 6 h.
B CDK4/6 knockdown is accompanied with a lower abundance of polyubiquitinated MYC. Control and CDK4/6-kd cells were treated with or without the proteasome
inhibitor MG132 for 6 h before collection for immunoprecipitation (IP). Samples were immunoprecipitated with MYC antibody and subjected to immunoblotting
using an anti-ubiquitin antibody.
C CDK4/6 knockdown is accompanied with decreased MYC phosphorylation. MYC, P-MYC Ser62, and P-MYC Thr58 protein levels were determined by Western blotting.
Bands were quantified by densitometry analysis (bottom) using the ImageJ software and represented as mean band intensity of P-MYC/MYC ratio normalized to
b-actin.
D Kinase assays of CDK4/Cyclin D1 and CDK6/Cyclin D1 on full-length recombinant human MYC protein. Results are expressed as percentage of MYC phosphorylation
as compared to RB phosphorylation by CDK4/Cyclin D1 and CDK6/Cyclin D1.
E Effects of CDK4/6 knockdown on signaling pathways. Western blotting analysis of total protein fractions of CDK4/6-kd and control cells under normoxic or hypoxic
(1% O2) conditions or after DMOG treatment for 24 h.
F Upregulation of GLS1, SLC7A6, SLC7A5, SLC3A2, and MAX in CDK4/6-kd cells. Gene expression was assessed by qRT–PCR. Results are normalized to cyclophilin A and
expressed as fold change relative to control cells.
G CDK4/6 knockdown induces activation of mTOR and Akt signaling pathways in HCT116 cells. Western blotting analysis of total protein fractions of CDK4/6-inhibited
and control cells.
H CDK4/6 knockdown induces activation of pyruvate dehydrogenase (PDH). Top, PDH activity in control and CDK4/6-kd cells. Bottom left, protein levels of PDH, P-PDH,
and PDK1, determined by Western blotting. Bottom right, gene expression levels of PDK1 and PDK3, quantified by qRT–PCR.
I Enhanced mitochondrial activity upon CDK4/6 knockdown in HCT116 cells estimated by MTT assays normalized by cell number.
J Western blotting analysis of total protein fractions of CDK4/6-inhibited and control MCF-7 and SK-BR-3 breast cancer cells. Protein extracts were obtained after
incubating MCF-7 and SK-BR-3 cells with PD0332991 (2 lM) or vehicle for 96 h.
K Cell cycle distribution of HCT116 cells synchronized by serum deprivation.
L Western blotting analysis of total protein fractions of CDK4/6-inhibited, serum-deprived, and control HCT116 cells.
M Comparative extracellular metabolic fluxes for serum-starved and control cells. Glucose and glutamine consumption and lactate and glutamate production rates
were obtained after 24 h of incubation with fresh media and normalized to cell number.
Data information: CDK4/6, CDK4/6-kd cells; Control, cells transfected with non-targeting RNA duplexes. Bars correspond to mean  SD (n = 3). Statistically significant
differences between CDK4/6-kd and control cells were determined by two-tailed independent sample Student’s t-tests and are indicated as P < 0.05 (*), P < 0.01 (**),
and P < 0.001 (***).
Source data are available online for this figure.
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caused a significant reduction in the viability of both control and
CDK4/6-kd cells. Importantly, the addition of the cell-permeable
form of a-ketoglutarate (aKG), dimethyl a-ketoglutarate (dm-
aKG), rescued the viability of BPTES-treated CDK4/6-kd cells
while it had no effect on control cells (Fig 6F). These observa-
tions indicate that the glutamine and glutaminase dependence
observed in CDK4/6-kd cells is not explained by the requirement
of amide groups and nitrogen for the biosynthesis of nucleotides
and non-essential amino acids, as dm-aKG is not able to fulfill
these glutamine-dependent reactions. These results are consistent
with the proposal that GLS1 inhibition is synthetic lethal with
MYC overexpression (Yuneva et al, 2012).
We next studied the effect of CDK4/6 and GLS1 inhibitors alone
and in constant ratio (1:4) combinations on the viability of HCT116
colorectal cancer and MCF-7 and SK-BR-3 breast cancer cells
(Fig 7A, see also Table EV4). The combination of PD0332991 and
BPTES in a wide dose range showed a strong synergistic antiprolif-
erative effect on all three cell lines. Strong synergistic effects were
also observed between PD0332991 and a second specific GLS1 inhi-
bitor, CB-839 (Gross et al, 2014).
Likewise, the combination of PD0332991 and the mTOR inhibitor
rapamycin exhibited a potent synergistic antiproliferative effect over
a wide dose range (CI < 0.1) (Fig 7A and Table EV4). We also
investigated whether the upregulation of PI3K/Akt in response to
CDK4/6 inhibition represented an additional cancer cell vulnerabil-
ity. Indeed, the combination of PD0332991 with the PI3K inhibitor
LY294002 showed a synergistic reduction of cell proliferation over a
wide dose range (Fig 7A and Table EV4), with the strongest syner-
gistic effects achieved at low dose combinations of PD0332991 and
LY294002.
None of the above drug combinations showed significant cyto-
toxic effects on non-cancerous BJ fibroblasts (Fig 7B; see alto
A
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Figure 5.
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Fig EV5A), endorsing these drug combinations as potential
chemotherapeutic therapies with selective antiproliferative activity
on cancer cells.
A further potential cancer cell vulnerability inferred from our
analysis was a compromised adaptation to hypoxia as a conse-
quence of CDK4/6 knockdown. Consistently, incubation for 24 h
A
D E F
B C
Figure 6. CDK4/6 knockdown results in enhanced MYC dependence.
A CDK4/6 knockdown sensitizes HCT116 cells to MYC inhibition. Top, Western blotting analysis of MYC protein expression in CDK4/6-kd and control cells after
treatment with 50 lM 10058-F4 or vehicle for 24 h. CDK, CDK4/6-kd cells; Ctr, cells transfected with non-targeting RNA duplexes. Bottom, CDK4/6-kd or control cells
were scored before and after treatment with 50 lM 10058-F4 or vehicle for 24 h.
B Inhibition of MYC reverts key molecular and signaling responses to CDK4/6 inhibition. Left, incubation of HCT116 cells with increased doses of 10058-F4 was
paralleled by downregulation of MYC, GLS1, P-mTOR, P-S6K, and P-Akt and upregulation of HIF-1a. b-actin signal was used as a Western blotting loading and
transfer control. Right, dose-dependent effects of 10058-F4 on the proliferation of HCT116 cells treated with PD0332991 (2 lM). Statistically significant differences are
indicated as P < 0.001 (***).
C MYC knockdown synergizes with CDK4/6 inhibition in its effects on HCT116 cell proliferation. Cells were counted 72 h and 96 h after siRNA transfection.
D Effect of MYC knockdown on the extracellular metabolic fluxes of CDK4/6-kd (top) and PD0332991-treated (bottom) cells. Glucose and glutamine consumption and
lactate and glutamate production rates were obtained after 24 h of incubation with fresh media and normalized to cell number. Results are expressed as percentage
to CDK4/6-inhibited cells consumption and production rates.
E Effect of CDK4/6 and MYC combined knockdown on protein levels assessed by Western blotting. Cells were transfected with MYC siRNA 24 h before analysis.
F CDK4/6 knockdown sensitizes HCT116 cells to GLS1 inhibition. Top, Percentages of viable cells after incubation with BPTES (10 lM), BPTES (10 lM) + aKG (2 mM),
under glutamine depletion or glutamine depletion + aKG (2 mM). Bottom, percentages of early apoptotic cells, assessed with the Annexin V-PI assay.
Data information: CDK4/6, CDK4/6-kd cells; Control, cells transfected with non-targeting RNA duplexes. Data are represented as mean  SD (n = 3). Significance was
determined by ANOVA and two-tailed independent sample Student’s t-tests. Statistically significant differences between CDK4/6-inhibited and control cells or MYC-kd
and control cells are indicated as P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), while differences between treatment and the corresponding control are shown as
P < 0.05 (#), P < 0.01 (##), and P < 0.001 (###) for CDK4/6-kd and as P < 0.05 (¶), P < 0.01 (¶¶), and P < 0.001 (¶¶¶) for control cells. All experiments were performed
96 h after siRNA transfection or PD0332991 treatment.
Source data are available online for this figure.
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under hypoxic conditions (1% O2) impaired the growth of CDK4/6-
kd cells while control cells were not significantly affected (Fig 7C).
In addition, incubation for 24 h with 1 mM DMOG also restrained
the proliferation of CDK4/6-kd cells to a greater extent than control
cells (Fig 7D).
In addition to affecting growth and viability of cancer cells in 2D
cultures, CDK4/6 knockdown reduced the anchorage-independent
growth of HCT116 cells (Fig 7E). The combinations of PD0332991
with 10058-F4, BPTES, rapamycin, LY294002, or DMOG reduced
spheroid growth significantly more than any of the drugs alone
(Fig 7E; see also Fig EV5B). Remarkably, the PD0332991–BPTES
combination caused the greatest and more selective effects.
Discussion
Our metabolic and transcriptomic analyses have allowed us to
precisely map the extensive metabolic reprogramming that follows
CDK4/6 depletion in HCT116 colorectal cancer cells, characterized
by an increase in mitochondrial metabolism and function accompa-
nied with an enhanced metabolism of glucose, glutamine and amino
acids. These observations are in agreement with those reported by
Franco et al, who also found that CDK4/6 inhibition leads to an
enhanced activation of the mTOR pathway and consequent sensitiv-
ity of pancreatic cancer cells to mTOR inhibitors (Franco et al,
2016). Significantly, our analysis identifies the accumulation of
MYC as the major upstream event that explains most aspects of the
metabolic reprogramming that follows CDK4/6 inhibition, including
upregulation of mTOR. We provide evidence that MYC is a direct
phosphorylation substrate of CDK4/6-Cyclin D1 complexes at Thr58
and Ser62, and depletion of CDK4/6 in HCT116 cells prevents the
phosphorylation of MYC at these two residues and its proteasome-
mediated degradation (Sears, 2000). As discussed below in more
detail, the consequent accumulation of MYC mechanistically
explains the simultaneous greater glutaminase dependence, down-
stream upregulation of the mTOR pathway and blunting of cellular
responses to hypoxia of CDK4/6-inhibited cells.
The enhanced glucose, glutamine, and amino acid metabolism
exhibited by CDK4/6-depleted cells can be explained by the ensuing
upregulation of MYC. MYC enhances glycolysis through the
activation of glycolytic and glucose transporters genes, promotes
lactate production and export, contributes to increase glutamine
uptake by upregulating the expression of glutamine transporters,
and enhances glutamine metabolism by transcriptionally repressing
microRNA-23a/b, resulting in a augmented expression of its target
glutaminase (GLS1) (Gao et al, 2009; Dang, 2013). GLS1 enhances
mitochondrial metabolism by catalyzing the conversion of gluta-
mine to glutamate, a key substrate for energy and redox processes,
including mitochondrial respiration, by fueling the TCA cycle
through its conversion to a-KG. Consistent with our results, it has
been described that pRB inhibition, whose phenotype is expected to
be the opposite to CDK4/6 loss, produces a decrease on TCA cycle
and mitochondrial respiration (Nicolay et al, 2015). Thus, our
observations point to a central role played by MYC-driven glutamine
metabolism in the metabolic reprogramming that follows CDK4/6
loss of function.
We have also found that CDK4/6 inhibition or knockdown is
accompanied with a baseline activation of the mTOR signaling path-
way, in line with prior evidences (Franco et al, 2016). It has been
described that the mTOR-negative regulators TSC1 and TSC2 are
phosphorylated and inactivated by CDK4/6, and inhibition of
CDK4/6 leads to active TSC1 and TSC2 and consequent inhibition of
mTOR (Zacharek et al, 2005). However, inhibition of CDK4/6 in our
experiments leads to enhanced, not diminished, baseline activation
of mTOR and thus a mechanism independent of a direct CDK4/6
regulation of mTOR must be invoked in order to explain our obser-
vations. Our study provides the following evidences in support of a
MYC-driven activation of mTOR in our system: First, MYC is known
to downregulate the mTOR-negative regulator TSC2 (Ravitz et al,
2007), as also found in our experiments. Second, the enhanced
glutaminolysis that follows MYC upregulation, in turn mediated by
downstream upregulation of SCL7A5 and GLS1 (Gao et al, 2009),
would also contribute to the observed enhanced mTOR activation
(Duran et al, 2012). In consequence, we believe that our proposal
that the upregulation of MYC following CDK4/6 inhibition is a
sound mechanism to explain the observed mTOR upregulation. A
third major phenotype induced by inhibition of CDK4/6 in our
cancer cell models is a limited response to hypoxia accompanied
with downregulation of HIF-1a, which can also be explained by the
accumulation of MYC. Increased levels of MYC and p-mTOR induce
▸Figure 7. Synergistic antiproliferative effects of PD0332991 in combination with glutaminase, mTOR, or PI3K-Akt inhibitors.A Synergistic antiproliferative effects between PD0332991 and BPTES, CB-839, rapamycin or LY294002. Cell viability was assessed by Hoechst staining after 96 h
incubation with the combinations of inhibitors at the indicated concentrations in HCT116 (left), MCF-7 (middle), and SK-BR-3 (right) cells. Results are shown as
percentage of proliferation relative to untreated cells (mean  SD of n = 6).
B The combinations of PD0332991 with BPTES, rapamycin, or LY294002 are not toxic to BJ fibroblasts. Cells were cultured at the indicated concentrations of inhibitors
for 96 h, and cell proliferation was determined by Hoechst staining. Results are shown as percentage of proliferation relative to untreated cells (mean  SD of n = 6).
C CDK4/6 knockdown sensitizes cells to hypoxia. CDK4/6-kd and control cells were incubated for 24 h under normoxic or hypoxic (1% O2) conditions.
D CDK4/6-kd and control cell viability after 24-h treatment with 1 mM DMOG. Results are shown as the percentage of proliferation relative to CDK4/6-kd and control
cells cultured with vehicle (100% proliferation).
E Combinations of PD0332991 with drugs showing synergistic inhibition of spheroid growth of HCT116 cells. Left, images of HCT116 spheroids after 10 days of
treatment with the indicated inhibitors. Right, quantification of total spheroid volume after treatment with the indicated drug combinations. Spheroids were scored
by image acquisition followed by spheroid area and volume quantification with ImageJ. Results are shown as percentage of total spheroid volume relative to
untreated cells. Data are represented as mean  SD (n = 5).
Data information: CDK4/6, CDK4/6-kd cells; Control, cells transfected with non-targeting RNA duplexes. Bars represent mean  SD (n = 3). Significance was determined
by Kruskal-Wallis and two-tailed independent sample Student’s t-tests. Statistically significant differences between CDK4/6-inhibited and control cells are indicated as
P < 0.01 (**) and P < 0.001 (***). Differences between treatment and the corresponding control are shown as P < 0.01 (##) and P < 0.001 (###) for CDK4/6-inhibited
cells and as P < 0.01 (¶¶) for control cells.
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glutamine transporters and GLS1, leading to both an increase of the
glutamine uptake and the intracellular concentration of a-KG which,
in turn, triggers the PHD2-mediated hydroxylation and subsequent
degradation of HIF-1a (Tennant et al, 2009). This scenario provides
a mechanistic explanation for the blunted adaptive responses and
augmented sensitivity to hypoxia observed in CDK4/6-inhibited cells.
In sum, our metabolic and transcriptomic analyses have revealed
that depletion or inhibition of CDK4/6 in cancer cells leads to de
novo addiction to MYC, and, as likely downstream consequences,
also to glutaminase and mTOR signaling, as well as to a compro-
mised adaptation to hypoxia. These dependencies reveal vulnerabil-
ities that can be exploited in therapeutic combinations with CDK4/6
inhibitors. This mechanism also helps explain previous observations
that CDK4 loss accelerates the development and increases the
tumorigenic potential of MYC-driven lymphoma (Lu et al, 2014).
Because of a lack of therapeutically efficacious MYC inhibitors (Li &
Simon, 2013), we propose the inhibition of MYC downstream
targets, in particular GLS1, as an effective strategy to overcome
acquired tolerance and resistance of cancer cells to CDK4/6 inhibi-
tors. This proposal is supported by the strong antiproliferative
synergies found in our experiments by combining CDK4/6 knock-
down or inhibition with the selective GLS1 inhibitors BPTES or CB-
839. Of particular interest is the limited cytotoxic activity observed
on non-malignant cells of GLS1 inhibitors as a single agent or in
pairwise combinations with the other drugs tested in this study,
which predicts for these combinations a significant therapeutic
margin in cancer management.
Materials and Methods
Full Materials and Methods are detailed in Appendix Supplementary
Methods.
Cell culture
Cells were obtained through the American Type Culture Collection
and grown in appropriate media at 37°C. For hypoxia incubations,
cells were kept in an atmosphere containing 1% oxygen and 5%
CO2 in a hypoxic incubator.
siRNA transfection
ON-TARGETplus SMARTpool siRNAs directed at CDK4 (L-003238-
00, GE Healthcare Dharmacon Inc., Lafayette, CO, USA) and
Silencer Select siRNA against CDK6 (s51, Ambion, Austin, TX, USA)
were transfected with Lipofectamine RNAiMAX (Invitrogen, Carls-
bad, CA, USA). As controls, ON-TARGETplus Non-Targeting Control
Pool siRNA (D-001810-10, GE Healthcare Dharmacon Inc.) and
Silencer Select Negative Control siRNA (4390844, Ambion) were
used.
Cell proliferation and viability assays
Proliferation assays were performed by flow cytometry combining
direct cell counting and propidium iodide staining. When testing
drugs that affect mitochondrial respiration, cell viability was
assessed by Hoechst staining measuring emitted fluorescence.
Measurement of extracellular metabolites
Glucose, lactate, glutamate and glutamine concentrations were
determined using a COBAS Mira Plus spectrophotometer (Horiba
ABX, Kyoto, Japan). Concentrations of non-essential and essential
amino acids were determined by ion-exchange chromatography.
Transcriptomic analysis
RNA was used to produce biotinylated cRNA that was hybridized to
Affymetrix GeneChip human genome U133 Plus 2.0 arrays (Affyme-
trix Inc., Santa Clara, CA, USA). Data were standardized using the
robust multi-array average (RMA) method (Irizarry et al, 2003) and
differential gene expression was assessed using the LIMMA package
(Smyth, 2004). GSEA (Subramanian et al, 2005) was applied to infer
gene signatures significantly associated with differentially expressed
genes.
13C-tracer-based metabolomics
Media samples and cell extracts were used to assess the isotopo-
logue distributions of extracellular and intracellular metabolites,
respectively. Isotopologue distribution analyses of 13C-labeled
metabolites were conducted by gas chromatography coupled to
mass spectrometry (GC/MS).
Oxygen consumption rate (OCR) and extracellular acidification
rate (ECAR)
OCR and ECAR were determined using a XF24 Extracellular Flux
Analyzer (Seahorse Bioscience, North Billerica, MA, USA).
Data and software availability
The primary datasets and computer code produced in this study are
available in the following databases: Microarray data: Gene Expres-
sion Omnibus GSE84597 (https://www.ncbi.nlm.nih.gov/geo/que
ry/acc.cgi?acc=GSE84597). Modeling computer scripts: Zenodo
database (https://doi.org/10.5281/zenodo.546717).
Expanded View for this article is available online.
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